Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice

Human Molecular Genetics

Volumn 21, Issue 10, 2012, Pages 2219-2232

  Pouladi, Mahmoud A ^a   Stanek, Lisa M ^b   Xie, Yuanyun ^a   Franciosi, Sonia ^a   Southwell, Amber L ^a   Deng, Yu ^a   Butland, Stefanie ^a   Zhang, Weining ^a   Cheng, Seng H ^b   Shihabuddin, Lamya S ^b   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALNEXIN; CANNABINOID 1 RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENKEPHALIN; HUNTINGTIN; MESSENGER RNA; MUTANT PROTEIN; PHOSPHOPROTEIN DARPP 32; SOMATOMEDIN C;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BLOOD LEVEL; BODY WEIGHT; BRAIN WEIGHT; CAG REPEAT; CEREBELLUM; COGNITION; CORPUS STRIATUM; FOREBRAIN; GENOMICS; HUNTINGTON CHOREA; LEARNING; MOTOR PERFORMANCE; MOUSE; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PLASMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STRAIN DIFFERENCE; TRANSCRIPTION REGULATION; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; TRANSGENES;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84860483495     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds037     Document Type: Article

References (53)

1. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
2. Hodgson, J.G., Smith, D.J., McCutcheon, K., Koide, H.B., Nishiyama, K., Dinulos, M.B., Stevens, M.E., Bissada, N., Nasir, J., Kanazawa, I. et al. (1996) Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum. Mol. Genet., 5, 1875-1885.
3. Menalled, L.B., Sison, J.D., Wu, Y., Olivieri, M., Li, X.-J., Li, H., Zeitlin, S. and Chesselet, M.-F. (2002) Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci., 22, 8266-8276.
4. Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., Li, H. and Li, X.-J. (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci., 23, 2193-2202.
5. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9, 1259-1271.
6. Schilling, G., Coonfield, M.L., Ross, C.A. and Borchelt, D.R. (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett., 315, 149-153.
7. Ferrante, R.J., Andreassen, O.A., Dedeoglu, A., Ferrante, K.L., Jenkins, B.G., Hersch, S.M. and Beal, M.F. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci., 22, 1592-1599.
8. Huntington Study Group. (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology, 57, 397-404.
9. Schiefer, J., Landwehrmeyer, G.B., Luesse, H.G., Sprunken, A., Puls, C., Milkereit, A., Milkereit, E. and Kosinski, C.M. (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord., 17, 748-757.
10. Landwehrmeyer, G.B., Dubois, B., de Yebenes, J.G., Kremer, B., Gaus, W., Kraus, P.H., Przuntek, H., Dib, M., Doble, A., Fischer, W. et al. (2007) Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol., 62, 262-272.
11. Hodgson, J.G., Agopyan, N., Gutekunst, C.A., Leavitt, B.R., LePiane, F., Singaraja, R., Smith, D.J., Bissada, N., McCutcheon, K., Nasir, J. et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23, 181-192.
12. Slow, E.J., van Raamsdonk, J., Rogers, D., Coleman, S.H., Graham, R.K., Deng, Y., Oh, R., Bissada, N., Hossain, S.M., Yang, Y.-Z. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555-1567.
13. Gray, M., Shirasaki, D.I., Cepeda, C., André, V.M., Wilburn, B., Lu, X.-H., Tao, J., Yamazaki, I., Li, S.-H., Sun, Y.E. et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182-6195.
14. Carroll, J.B., Warby, S.C., Southwell, A.L., Doty, C.N., Greenlee, S., Skotte, N., Hung, G., Bennett, C.F., Freier, S.M. and Hayden, M.R. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene/allele-specific silencing of mutant Huntingtin. Mol. Ther., 19, 2178-2185.
15. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S. and Sunyaev, S.R. (2010) A method and server for predicting damaging missense mutations. Nat. Meth., 7, 248-249.
16. Consortium, I.H., Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve, L.L., Gibbs, R.A., Belmont, J.W., Boudreau, A., Hardenbol, P. et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851-861.
17. Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M. and Sirotkin, K. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res., 29, 308-311.
18. Ehrnhoefer, D.E., Sutton, L. and Hayden, M.R. (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist, 17, 475-492.
19. Robertson, G., Bilenky, M., Lin, K., He, A., Yuen, W., Dagpinar, M., Varhol, R., Teague, K., Griffith, O.L., Zhang, X. et al. (2006) cisRED: a database system for genome-scale computational discovery of regulatory elements. Nucleic Acids Res., 34, D68-D73.
20. Andersen, M.C., Engström, P.G., Lithwick, S., Arenillas, D., Eriksson, P., Lenhard, B., Wasserman, W.W. and Odeberg, J. (2008) In silico detection of sequence variations modifying transcriptional regulation. PLoS Comput. Biol., 4, e5.
21. Friedman, R.C., Farh, K.K.-H., Burge, C.B. and Bartel, D.P. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res., 19, 92-105.
22. Goldberg, Y.P., McMurray, C.T., Zeisler, J., Almqvist, E., Sillence, D., Richards, F., Gacy, A.M., Buchanan, J., Telenius, H. and Hayden, M.R. (1995) Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum. Mol. Genet., 4, 1911-1918.
23. Van Raamsdonk, J.M., Gibson, W.T., Pearson, J., Murphy, Z., Lu, G., Leavitt, B.R. and Hayden, M.R. (2006) Body weight is modulated by levels of full-length huntingtin. Hum. Mol. Genet., 15, 1513-1523.
24. Pouladi, M.A., Xie, Y., Skotte, N.H., Ehrnhoefer, D.E., Graham, R.K., Kim, J.E., Bissada, N., Yang, X.W., Paganetti, P., Friedlander, R.M. et al. (2010) Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum. Mol. Genet., 19, 1528-1538.
25. Pouladi, M.A., Graham, R.K., Karasinska, J.M., Xie, Y., Santos, R.D., Petersén, A. and Hayden, M.R. (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 132, 919-932.
26. Van Raamsdonk, J.M., Pearson, J., Slow, E.J., Hossain, S.M., Leavitt, B.R. and Hayden, M.R. (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci., 25, 4169-4180.
27. Richfield, E.K., Maguire-Zeiss, K.A., Cox, C., Gilmore, J. and Voorn, P. (1995) Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann. Neurol., 37, 335-343.
28. Augood, S.J., Faull, R.L. and Emson, P.C. (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol., 42, 215-221.
29. Augood, S.J., Faull, R.L., Love, D.R. and Emson, P.C. (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience, 72, 1023-1036.
30. Desplats, P.A., Kass, K.E., Gilmartin, T., Stanwood, G.D., Woodward, E.L., Head, S.R., Sutcliffe, J.G. and Thomas, E.A. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem., 96, 743-757.
31. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet., 19, 233-238.
32. Okazawa, H. (2003) Polyglutamine diseases: a transcription disorder? Cell. Mol. Life Sci., 60, 1427-1439.
33. Sathasivam, K., Woodman, B., Mahal, A., Bertaux, F., Wanker, E.E., Shima, D.T. and Bates, G.P. (2001) Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Hum. Mol. Genet., 10, 2425-2435.
34. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A.S. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA, 100, 2041-2046.
35. Menalled, L., El-Khodor, B.F., Patry, M., Suárez-Fariñas, M., Orenstein, S.J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X.W., MacDonald, M. et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319-336.
36. Van Raamsdonk, J.M., Pearson, J., Bailey, C.D.C., Rogers, D.A., Johnson, G.V.W., Hayden, M.R. and Leavitt, B.R. (2005) Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J. Neurochem., 95, 210-220.
37. Graham, R.K., Deng, Y., Slow, E.J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z. et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 125, 1179-1191.
38. Swerdlow, N.R., Paulsen, J., Braff, D.L., Butters, N., Geyer, M.A. and Swenson, M.R. (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J. Neurol. Neurosur. Psychiatry, 58, 192-200.
39. Svenningsson, P., Tzavara, E.T., Carruthers, R., Rachleff, I., Wattler, S., Nehls, M., McKinzie, D.L., Fienberg, A.A., Nomikos, G.G. and Greengard, P. (2003) Diverse psychotomimetics act through a common signaling pathway. Science, 302, 1412-1415.
40. Metzler, M., Gan, L., Mazarei, G., Graham, R.K., Liu, L., Bissada, N., Lu, G., Leavitt, B.R. and Hayden, M.R. (2010) Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci., 30, 14318-14329.
41. Van Raamsdonk, J.M., Pearson, J., Rogers, D.A., Bissada, N., Vogl, A.W., Hayden, M.R. and Leavitt, B.R. (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 14, 1379-1392.
42. Van Raamsdonk, J.M., Pearson, J., Rogers, D.A., Lu, G., Barakauskas, V.E., Barr, A.M., Honer, W.G., Hayden, M.R. and Leavitt, B.R. (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp. Neurol., 196, 266-272.
43. Van Raamsdonk, J.M., Murphy, Z., Slow, E.J., Leavitt, B.R. and Hayden, M.R. (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 14, 3823-3835.
44. Graham, R.K., Slow, E.J., Deng, Y., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Leavitt, B.R., Raymond, L.A. and Hayden, M.R. (2006) Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis., 21, 444-455.
45. Miller, J., Arrasate, M., Brooks, E., Libeu, C.P., Legleiter, J., Hatters, D., Curtis, J., Cheung, K., Krishnan, P., Mitra, S. et al. (2011) Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol., 7, 925-934.
46. Andrew, S.E., Goldberg, Y.P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., Kalchman, M.A. et al. (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet., 4, 398-403.
47. Brinkman, R.R., Mezei, M.M., Theilmann, J., Almqvist, E. and Hayden, M.R. (1997) The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am. J. Hum. Genet., 60, 1202-1210.
48. Langbehn, D.R., Brinkman, R.R., Falush, D., Paulsen, J.S. and Hayden, M.R. (2004) A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet., 65, 267-277.
49. Squitieri, F., Gellera, C., Cannella, M., Mariotti, C., Cislaghi, G., Rubinsztein, D.C., Almqvist, E.W., Turner, D., Bachoud-Levi, A.C., Simpson, S.A. et al. (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain, 126, 946-955.
50. Sobczak, K., de Mezer, M., Michlewski, G., Krol, J. and Krzyzosiak, W.J. (2003) RNA structure of trinucleotide repeats associated with human neurological diseases. Nucleic Acids Res., 31, 5469-5482.
51. Mykowska, A., Sobczak, K., Wojciechowska, M., Kozlowski, P. and Krzyzosiak, W.J. (2011) CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res., 39, 8938-8951.
52. Sobczak, K. and Krzyzosiak, W.J. (2005) CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. J. Biol. Chem., 280, 3898-3910.
53. Cryan, J.F., Markou, A. and Lucki, I. (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci., 23, 238-245.